Background
==========

The rapid increase in infections caused by antibiotic-resistant Gram-negative bacteria, such as carbapenem-resistant Enterobacteriaceae, has raised great concern worldwide. Colistin was used as an alternative therapy to treat infections caused by multidrug-resistant (MDR) Gram-negative bacteria.[@b1-idr-11-1597] Colistin was one of the few options for such type of bacterial infections. As colistin is currently used for treating human or animal infections, an increasing number of colistin and drug resistance mechanisms are reported.[@b2-idr-11-1597],[@b3-idr-11-1597] Nevertheless, the prevalence of the colistin-resistant issue has gained worldwide attention. *Mcr-1* genes were first reported as mediated by plasmid and can be spread between different bacteria through plasmids. Previously, the primary mechanism underlying colistin resistance stated that the bacterial chromosome coding of the binary regulatory system pmr AB and pho PQ and the associated regulatory gene *mgr B* mutations led to altered lipid A modification, thereby reducing the affinity of bacteria for polymyxin.[@b4-idr-11-1597] In 2015, some investigators identified a novel mechanism mediating the low level of resistance to colistin.[@b5-idr-11-1597] These resistant strains carry a novel gene *mcr-1* encoding phosphoethanolamine transferase that reduces the affinity of colistin to lipopolysaccharide, which was identified on an IncI2 plasmid and pHNSHP45, isolated from an *Escherichia coli* isolate from a pig in China; thus, these bacteria are not deemed sensitive to colistin.[@b6-idr-11-1597],[@b7-idr-11-1597] Currently, the *mcr-1* gene has been detected in approximately 40 countries. The distribution of these plasmids among carbapenem-resistant organisms might produce "super bacteria."

Herein, we aimed to determine the prevalence of *mcr-1* gene in a Chinese-teaching hospital and understand its molecular characteristics. Furthermore, we assessed the prognostic impact of this gene on clinical patients and the drug resistance of patients infected with *mcr-1*-positive strains. Hence, monitoring the resistance of colistin, delaying the spread of bacterial resistance, and providing effective advice for clinical treatment are essential.

Methods
=======

Clinical bacterial isolates
---------------------------

The clinical isolates were collected from the Microbiology Laboratory of Anhui Medical University Union Hospital (Heifei, Anhui, China) from January 2015 to 2016, which is the largest tertiary hospital in Anhui Province, Central China. The inclusion criteria were distinct for the diagnosis of bacterial infections. All the isolates were identified using the Gram-negative bacteria identification card of the Vitek system (BioMèrieux, Missouri, France).

Extract template DNA
--------------------

Several monoclonal bacterial colonies were suspended in 100 µL of sterile distilled water and heated at 100°C for 10 minutes and centrifuged at 10,000× *g* for 10 minutes. The resulting supernatant contained the bacterial genomic DNA.

*mcr-1* screening
=================

The primers for the PCR amplification of *mcr-1* gene were as follows: mcr-1-forward (5′-GCTCGGTCAGTCCGTTTG-3′) and mcr-1-reverse (5′-GAATGCGGTGCGGTCTTT-3′). A total of 35 cycles were conducted as follows: 94°C predenaturation for 5 minutes, 94°C denaturation for 1 minute, 55°C annealed 30 seconds, and 72°C extension for 1 minute. The PCR products were analyzed by agarose gel electrophoresis ([Figure 1](#f1-idr-11-1597){ref-type="fig"}), and the positive products were sequenced.

Molecular typing
================

Pulsed-field gel electrophoresis (PFGE) was used for the molecular typing of six *mcr-1*-positive strains. The bacteria were embedded in SeaKem Gold Agarose (Lonza, Rockland, MD, USA), and the genome was subjected to restriction cleavage using *XbaI*. Subsequently, the DNA fragments were electrophoresed by the CHEF-mapper XA PFGE system (Bio-Rad Laboratories Inc., Hercules, CA, USA) for 22 hours at 14°C, 6 V/cm, and from 5 to 35 seconds pulses. The PFGE patterns were compared using BioNumerics Version 7.6. Furthermore, whole genome sequencing was used for determining the molecular typing and all the resistance genes.

*mcr-1*-resistant gene detection and analysis
---------------------------------------------

The *mcr-1* DNA was digested using the S1 nuclease (Takara, Otsu, Japan), and then, the genomic DNA resolved by PFGE system for 18 hours at 14°C with 2.16--63.8 seconds pulses. The DNA fragments were transferred to nylon membrane (EMD Millipore, Billerica, MA, USA) that was hybridized with digoxigenin-labeled *mcr-1*-specific probes in the hybridization oven at 40°C overnight. The NBT/BCIP color detection kit (Hoffman-La Roche Ltd., Basel, Switzerland) was used for staining the nylon membrane after hybridization.

We used filter mating to investigate whether the *mcr-1*-resistant gene can be transferred. *E. coli* EC600 with rifampicin resistance was employed as the recipient strain; all the *mcr-1*-positive isolates were tested, ratio of the donor and recipient strains was 1:1, and the agar with colistin (4 mg/L) and rifampicin (700 mg/L) was utilized for selection. The transconjugants were demonstrated as *mcr-1* positive by PCR and further validated by PFGE. Then, the plasmids from *mcr-1*-positive transconjugants were extracted. Next, a strain of *Klebsiella pneumoniae* was preserved at the Department of Microbiology of our hospital. The growth did not produce mucus on the plate and resistance to imipenem; *K. pneumoniae* served as the recipient strain. The recipient bacteria were mixed with the extracted plasmid in a ratio of 10:1, and the electrotransformation mixture was set at a voltage of 2.1 kV. The electrotransformed mixture was incubated in the broth for 3 hours and allowed to grow overnight on plates containing polymyxin (2 mg/L).

Antimicrobial susceptibility testing (AST)
------------------------------------------

All mcr-1-positive specimens were tested for AST. The antimicrobial agents tested included meropenem, imipenem, tigecycline, colistin, aztreonam, amikacin, levofloxacin, cefoperazone-sulbactam, cefotaxime, cefepime, and trimethoprim/sulfamethoxazole. The Clinical and Laboratory Standards Institute (CLSI) was used to explain the results of AST.[@b8-idr-11-1597] *E*-test was used for supplementing the susceptibility testing, and the results were interpreted based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints.[@b9-idr-11-1597] *E. coli* 25922 was used as a standard quality control strain.

Gene sequence analysis
----------------------

Positive strains were analyzed by whole-genome sequencing.

Clinical data collection
------------------------

The clinical data including specimen type, age, sex, infection type, and clinical outcomes were collected from patients. These patients exhibited a clear infection during hospitalization. Also, they were treated with antibiotics during the hospital stay. The cases of these patients were analyzed retrospectively.

Results
=======

In this study, we collected 1,112 nonduplicate clinical infection isolates from patients. Of these isolates, six (0.6%) strains carried the *mcr-1* gene, which was similar to that reported previously.[@b10-idr-11-1597]--[@b13-idr-11-1597] These *mcr-1*-positive isolates were collected from five different departments. The age of the patients ranged from 30 to 70 years, except for one of the patients, who was only 3 months old. The baseline data of the patients with *mcr-1*-positive *E. coli* infection are shown in [Table 1](#t1-idr-11-1597){ref-type="table"}. In addition, AST was estimated in all positive isolates and the MIC of colistin ranged from 4 to 16 mg/L, indicating a low level of resistance to polymyxin. Of the six *mcr-1*-positive isolates, a majority were susceptible to tigecycline, amikacin, cefoperazone sulbactam, meropenem, and imipenem, while only one was susceptible to levofloxacin, aztreonam, and trimethoprim/sulfamethoxazole, and all isolates were resistant to polymyxin, cefotaxime, and cefepime. The characteristics of *mcr-1*-positive isolates are shown in [Tables 1](#t1-idr-11-1597){ref-type="table"}[](#t2-idr-11-1597){ref-type="table"}--[3](#t3-idr-11-1597){ref-type="table"}.

Mcr-1 was usually found to be present in the bacterial genome with other resistance genes, such as *ESBL*.[@b23-idr-11-1597] Nevertheless, all the six positive isolates were susceptible to carbapenems and meropenem. Moreover, the whole genome sequencing did not show any coexistence of carbapenem-resistant genes with *mcr-1*. We also found that the ESBL genes, including *blaTEM-1B*, *blaCTX-M14*, *blaCTX-M132*, *blaCTX-M55*, and *blaCTX-M123* were contained in the genomes of these six strains that can lead to resistance to antibiotics, such as cephalosporins and penicillins. Notably, these strains contain other resistance genes: *fosA3*, *fosA*, *aph*(*4*)-*Ia*, *sul2*, *oqxA*, *oqxB*, and *aadA2*. A large number of studies have found that the transfer of the *mcr-1* gene was usually associated with the movable element *ISApl1-mcr-1*. Our sequencing analysis did not reveal significant differences around the *mcr-1* gene in the six *mcr-1*-positive strains, and two genetic environments were detected ([Figure 2](#f2-idr-11-1597){ref-type="fig"}). We did not find the *IsApl1* insert upstream to the *mcr-1* gene, rather the *pap-2* gene was found downstream to the *mcr-1* gene. Thus, we speculated that the *ISApl1* gene may be recombined, resulting in only partial sequences remaining upstream of *mcr-1*.

XbaI-PFGE ([Figure 3](#f3-idr-11-1597){ref-type="fig"}) showed that these *mcr-1*-positive strains were divided into six genotypes that indicated non-clonal transmission. The six *mcr-1*-positive strains were grouped into six distinct sequence types (STs) that were highly heterogeneous and a variety of plasmid type bacteria that carry *mcr-1*.

In the current filter mating study, two strains were successfully transferred to EC600 simultaneously, while the remaining four strains were tested two times, suggesting that all the *mcr-1* genes were harbored in the plasmids. After 1 week of continuous subculture, the transconjugants can still detect the mcr-1 gene after PCR verification, which proves that the plasmid carrying mcr-1 can be stable in the transconjugants. In the plasmid conjugation test, the transconjugants did not grow on the plates, which might be attributed to the low efficiency of electrotransformation. This phenomenon might be related to the bacterial characteristics of *K. pneumoniae*.

The results of the S1 nuclease digestion ([Figure 4](#f4-idr-11-1597){ref-type="fig"}) and Southern blot analysis ([Figure 5](#f5-idr-11-1597){ref-type="fig"}) showed that the *mcr-1* genes were localized on the following three different types of plasmids: approximately 33, 61, and \>92 kb.

Discussion
==========

The current study showed that the *mcr-1* gene could be detected in various *Enterobacteriaceae* bacteria, including *E. coli*, *K. pneumoniae*, *Salmonella*, and *Enterobacter cloacae*, and reported in several countries.[@b14-idr-11-1597]--[@b18-idr-11-1597] Some studies demonstrated that the *mcr-1* gene could be transmitted through the food chain model, leading to its widespread occurrence in poultry farming, and sources of water contaminated with *mcr-1* can also be considered as another route of transmission beyond the chain.[@b5-idr-11-1597],[@b12-idr-11-1597],[@b19-idr-11-1597]--[@b21-idr-11-1597] The following two cases of *mcr-1*-positive *E. coli* were identified in the population: infected bacteria and fixed-value bacteria; the use of antibiotics and the patient's immunosuppression are the putative causes of the epidemic.[@b24-idr-11-1597] Currently, the detection of human *Enterobacter mcr-1* has been reported in various countries at a rate of 1--2%, which is significantly lower than that of the animal sources.[@b5-idr-11-1597],[@b12-idr-11-1597] Usually, the *mcr-1* gene coexists with other drug-resistant genes, which is in agreement with the current study. Other drug-resistant genes copromote *mcr-1* that might indicate a selective role for mcr-1 and promote its epidemic spread; however, the underlying mechanism is not yet clarified. Based on the relevant research results, the lack of appropriate pressure selection did not prompt the occurrence of *mcr-1* in the human body for a prolonged period.[@b18-idr-11-1597]

More than 10 plasmids have been found to carry the *mcr-1* gene, including *IncX4*, *Incl2*, *IncP*, *IncX3-IncX4*, *IncFII*, *Incl2-IncFIB*, *IncFI*, *IncX1-IncX2*, *IncHI1*, and *IncHI2*. The most prevalent plasmids are IncHI2, Inc2, and Inc2, followed by IncX4 and other plasmids. The genome of these plasmids carries the *mcr-1* gene, as well as, other drug-resistant genes, leading to the cotransmission of multiple drug-resistant genes. The insertion sequence ISApl1 is often detected upstream or downstream of the *mcr-1* gene, and this mobile element causes the spread of *mcr-1* gene. Some studies have shown that the *mcr-1* gene can be inserted into other plasmids by its upstream and downstream looping in ISApl1.[@b22-idr-11-1597]

Nevertheless, the current study showed that the prevalence of colistin resistance was extremely low in *E. coli* based on the clinical infections in the hospital. This result was similar to that of the previous study.[@b5-idr-11-1597],[@b10-idr-11-1597]--[@b13-idr-11-1597] However, we need to further expand the number of strains and the sample collection areas. The diversity of PFGE types and STs showed that all of these *mcr-1*-positive isolates were from sporadic cases, and this low prevalence might be the background of the presence of the *mcr-1* gene in microorganisms; however, additional data are essential for the substantiation of these findings. Hitherto, according to the results of Chinese studies, the *mcr-1* gene has a high prevalence rate in animals and a low prevalence rate in hospital patients.[@b10-idr-11-1597],[@b25-idr-11-1597],[@b26-idr-11-1597] Furthermore, in China, due to the large quantities of polymyxin used in agriculture and animal husbandry, the spread of *mcr-1* gene between bacteria cannot be ignored. Although no *mcr-1*-positive *K. pneumoniae* was detected in the collected isolates in this study, a low level of *mcr-1* prevalence was detected in *K. pneumoniae*.[@b5-idr-11-1597],[@b12-idr-11-1597],[@b14-idr-11-1597]--[@b18-idr-11-1597] Considering that less clinical data are available for *mcr-1*, we aimed to establish an animal infection model to understand the correlation between the new resistance genes and other resistance genes and the threat to human infection.

mcr-1 can be transmitted between the natural environment, human body, and different strains through different transfer elements. Therefore, we can control the spread of mcr-1 by several effective measures. mcr-1 spreads in the hospital environment in the absence of colistin. Thus, patients with mcr-1 infection in the hospital, ward environment, medical equipment, as well as, doctors should be monitored promptly to administer antibiotics effectively in order to prevent the prevalence of *mcr-1* in the hospital.

The major concern for the clinicians is the *mcr-1* transfer into carbapenemase producers in a hospital setting, which could lead to the production of pandrug-resistant (PDR) strain.[@b27-idr-11-1597],[@b28-idr-11-1597] Thus, effective measures are imperative to monitor the prevalence of multislime resistance, thereby preventing the further spread of bacterial resistance.

Conclusion
==========

The current study showed that the *mcr-1* gene was responsible for the majority of colistin resistance in clinical isolates of *E. coli*. The gene can be transferred into plasmids containing other drug resistance genes by plasmid-DNA conjugation, which might cause severe consequences in drug-resistant strains. Thus, the widespread popularity of *mcr-1* gene should be prevented.
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![PCR products from six *mcr-1*-positive isolates.\
**Notes:** 1: marker, DL2000; 2: positive control; 3: E4857; 4: E6512; 5: E0964; 6: E2069; 7: E9497; 8: E1825; and 9: negative control.](idr-11-1597Fig1){#f1-idr-11-1597}

![Two representative*mcr-1* gene environments.](idr-11-1597Fig2){#f2-idr-11-1597}

![Cluster analysis of six strains of bacteria by *XbaI* digestion.](idr-11-1597Fig3){#f3-idr-11-1597}

![S1-digested plasmid DNA.\
**Notes:** M: *Salmonella* H9812 (20.5--1135 kb); 1: E1825; 2: E9497; 3: E2069; 4: E0964; 5: E6512; and 6: E4857. The arrow in the figure represents the position of the *mcr-1* plasmid.](idr-11-1597Fig4){#f4-idr-11-1597}

![Southern blot hybridization of *E. coli* isolates with *mcr-1*.\
**Notes:** 1: E1825; 2: E9497; 3: E2069; 4: E0964; 5: E6512; and 6: E485.\
**Abbreviation:** *E. coli*, *Escherichia coli*.](idr-11-1597Fig5){#f5-idr-11-1597}

###### 

Clinical information of six patients with *mcr-1*-positive specimens

  Isolates   Department             Specimen   Gender   Age        Underlying diseases                             Length of hospital stay (days)   Treatments used                                 Outcomes
  ---------- ---------------------- ---------- -------- ---------- ----------------------------------------------- -------------------------------- ----------------------------------------------- ----------
  E6512      Nephrology             Urine      Female   30 years   Diabetes, urinary tract infection               6                                Cefoxitin, levofloxacin                         Cured
  E1825      Urinary surgery        Urine      Female   36 years   Pyelolithotomy, percutaneous nephrostomy        20                               Cefoperazone sulbactam, imipenem, meropenem     Cured
  E2069      Pediatric department   Sputum     Male     5 months   Severe pneumonia, mechanical ventilation        15                               Ceftriaxone, erythromycin, imipenem             Cured
  E9497      Burns surgery          Pus        Male     48 years   Hypertension, history of spinal surgery         40                               Cefoperazone, sulbactam, vancomycin, imipenem   Cured
  E0964      Urinary surgery        Urine      Female   62 years   Hypertension, urinary tract infection           9                                Ceftriaxone, imipenem, rifamycin                Cured
  E4857      Dermatology            Pus        Male     70 years   Hypertension, skin and soft tissue infections   24                               Mezlocillin sulbactam, imipenem, gentamicin     Cured

###### 

Characteristics of colistin-resistant and mcr-1-positive isolates

  Isolates   Number of mcr plasmid   Location of mcr-1         Antimicrobials isolate was susceptible to                             ST        MIC of colistin (mg/L)
  ---------- ----------------------- ------------------------- --------------------------------------------------------------------- --------- ------------------------
  E1825      1                       Plasmid, 61 kb            Meropenem, imipenem, amikacin                                         ST 457    4
  E2069      1                       Plasmid, 33 kb            Tigecycline, levofloxacin, amikacin, meropenem                        ST 160    4
  E0964      2                       Plasmid, 33 and 61 kb     Imipenem, Trimethoprim/sulfamethoxazole, cefoperazone sulbactam       ST 6706   8
  E4857      2                       Plasmid, 61 and \>92 kb   Meropenem, imipenem, tigecycline, cefoperazone sulbactam, aztreonam   ST 2847   8
  E6512      1                       Plasmid, 61 kb            Meropenem, imipenem, tigecycline, cefoperazone sulbactam, amikacin    ST 156    8
  E9497      1                       Plasmid, 33 kb            Meropenem, imipenem, tigecycline, cefoperazone sulbactam, amikacin    ST 354    16

**Note:** In the first column, the first number represents the isolate of *E. coli* and the latter numbers represent the bacteria number.

**Abbreviations:** *E. coli*, *Escherichia coli*; ST, sequence type.

###### 

Drug sensitivity test value of *mcr-1*-positive strain

  Isolates   CTX     FEP     TGC   MEM         IPM     LEV      AK      CO   ATM     TS      CPS
  ---------- ------- ------- ----- ----------- ------- -------- ------- ---- ------- ------- -----
  E1825      \>256   \>256   4     0.125       0.25    256      2       4    \>265   \>32    48
  E2069      \>256   \>256   0.5   \<0.03125   0.25    \<0.25   4       4    32      0.047   32
  E0964      \>256   \>256   1     \<0.03125   0.125   64       \>256   8    32      \>32    16
  E4857      128     128     0.5   \<0.03125   0.125   32       \>256   8    6       \>32    16
  E6512      \>256   \>256   0.5   0.0625      0.125   4        16      8    64      \>32    32
  E9497      \>256   \>256   1     0.0625      0.125   32       8       16   48      \>32    6

**Note:** The data in the table represent the MIC value of each drug.

**Abbreviations:** AK, amikacin; ATM, aztreonam; CO, colistin; CPS, cefoperazone sulbactam; CTX, cefotaxime; FEP, cefepime; IPM, imipenem; LEV, levofloxacin; MEM, meropenem; TGC, tigecycline; TS, trimethoprim/sulfamethoxazole.
